IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-0.97%)
Close on Nov 19, 2026Market cap $7.61MP/E –Yield –
IN8bio shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
IN8bio's shares outstanding was 19M at Jun 30, 2026. For fiscal 2025 it was 4M, up 145.1% from the year before. The highest annual figure on record is 4M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4M | +145.1% |
| FY2024 | Dec 31, 2024 | 2M | +79.3% |
| FY2023 | Dec 31, 2023 | 1M | +42.4% |
| FY2022 | Dec 31, 2022 | 1M | +110.3% |
| FY2021 | Dec 31, 2021 | 0M | +191.6% |
| FY2020 | Dec 31, 2020 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 19M | +372.6% |
| Q1 FY2026 | Mar 31, 2026 | 19M | +655.9% |
| Q4 FY2025 | Dec 31, 2025 | 7M | +173.7% |
| Q3 FY2025 | Sep 30, 2025 | 5M | +187.7% |
| Q2 FY2025 | Jun 30, 2025 | 4M | +162.9% |
| Q1 FY2025 | Mar 31, 2025 | 3M | +78.5% |
| Q4 FY2024 | Dec 31, 2024 | 3M | +124.8% |
| Q3 FY2024 | Sep 30, 2024 | 2M | +50.0% |
| Q2 FY2024 | Jun 30, 2024 | 2M | +65.1% |
| Q1 FY2024 | Mar 31, 2024 | 1M | +75.0% |
| Q4 FY2023 | Dec 31, 2023 | 1M | +41.1% |
| Q3 FY2023 | Sep 30, 2023 | 1M | +45.6% |
| Q2 FY2023 | Jun 30, 2023 | 1M | +51.2% |
| Q1 FY2023 | Mar 31, 2023 | 1M | +31.6% |
| Q4 FY2022 | Dec 31, 2022 | 1M | +30.1% |
| Q3 FY2022 | Sep 30, 2022 | 1M | +61.9% |
| Q2 FY2022 | Jun 30, 2022 | 1M | +400.2% |
| Q1 FY2022 | Mar 31, 2022 | 1M | +399.4% |
| Q4 FY2021 | Dec 31, 2021 | 1M | +447.5% |
| Q3 FY2021 | Sep 30, 2021 | 0M | +270.1% |
| Q2 FY2021 | Jun 30, 2021 | 0M | +8.7% |
| Q1 FY2021 | Mar 31, 2021 | 0M | – |
| Q4 FY2020 | Dec 31, 2020 | 0M | – |
| Q3 FY2020 | Sep 30, 2020 | 0M | – |
| Q2 FY2020 | Jun 30, 2020 | 0M | – |
See a number that looks wrong?